TY  - JOUR
AU  - Bousman, CA
AU  - Mueller, DJ
AU  - Ng, CH
AU  - Byron, K
AU  - Berk, M
AU  - Singh, AB
Y2  - 2020/12/21
Y1  - 2017/01/01
SN  - 1744-6872
UR  - http://hdl.handle.net/11343/257050
AB  - BACKGROUND: Pharmacogenetic-based dosing support tools have been developed to personalize antidepressant-prescribing practice. However, the clinical validity of these tools has not been adequately tested, particularly for specific antidepressants. OBJECTIVE: To examine the concordance between the actual dose and a polygene pharmacogenetic predicted dose of desvenlafaxine needed to achieve symptom remission. MATERIALS AND METHODS: A 10-week, open-label, prospective trial of desvenlafaxine among Caucasian adults with major depressive disorder (n=119) was conducted. Dose was clinically adjusted and at the completion of the trial, the clinical dose needed to achieve remission was compared with the predicted dose needed to achieve remission. RESULTS: Among remitters (n=95), there was a strong concordance (Kendall's τ-b=0.84, P=0.0001; Cohen's κ=0.82, P=0.0001) between the actual and the predicted dose need to achieve symptom remission, showing high sensitivity (≥85%), specificity (≥86%), and accuracy (≥89%) of the tool. CONCLUSION: Findings provide initial evidence for the clinical validity of a polygene pharmacogenetic-based tool for desvenlafaxine dosing.
LA  - English
PB  - LIPPINCOTT WILLIAMS & WILKINS
T1  - Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study
DO  - 10.1097/FPC.0000000000000253
IS  - Pharmacogenetics and Genomics
VL  - 27
IS  - 1
SP  - 1-6
L1  - /bitstream/handle/11343/257050/PMC5152629.pdf?sequence=1&isAllowed=y
ER  -